Parenteral or intranasal immunization with HIV gp160 formulated with proteosomes and/or PA adjuvants enhances epitope-specific IgG or IgA.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Parenteral or intranasal immunization with HIV gp160 formulated with proteosomes and/or PA adjuvants enhances epitope-specific IgG or IgA.

Abstr Gen Meet Am Soc Microbiol. 1994;94:155 (abstract no. E-70). Unique Identifier : AIDSLINE ASM94/94313068
Kaminski R; Amselem S; Levi M; Loomis L; Kersey K; Vancott T; Friedman D; Smith G; Wahren B; Redfield R; et al; Walter Reed Army Institute of Research, Washington, DC.

Abstract: We have immunized mice i.m. or intranasally and rabbits i.m. with HIV gp160 (MicroGeneSys) formulated with alum or proprietary adjuvants (PA, Pharmos) and/or meningococcal outer membrane protein proteosomes. When administered i.m., proteosomes plus alum or PA formulations (with or without proteosomes) induced improved and broadened immune responses against several gp160 epitopes compared to the standard gp160 alum-adjuvanted vaccine in both mice and rabbits. Moreover, either PA or proteosomes dramatically enhanced immunogenicity following intranasal immunization and proteosome formulation markedly boosted IgA responses. Data analyzed using a combination of ELISA, quantitative Western Blot and PEPscan techniques show that altering the presentation, formulation and route of administration of gp160 influences both quantitative and qualitative aspects of epitope specific IgG and IgA immune responses. These data are encouraging for the development of enhanced i.m. or intranasal sub-unit formulations of gp160 vaccines for HIV vaccine therapy.

Keywords: Adjuvants, Immunologic Administration, Intranasal Alum Compounds Animal AIDS Vaccines/*ADMINISTRATION & DOSAGE/IMMUNOLOGY Comparative Study Cysteine Proteinases Drug Carriers Epitopes/ANALYSIS Gene Products, env/ADMINISTRATION & DOSAGE/*IMMUNOLOGY HIV/*IMMUNOLOGY HIV Antibodies/ANALYSIS/BIOSYNTHESIS IgG/ANALYSIS/*BIOSYNTHESIS IgM/ANALYSIS/*BIOSYNTHESIS Injections, Intramuscular Mice Multienzyme Complexes Protein Precursors/ADMINISTRATION & DOSAGE/*IMMUNOLOGY Rabbits ABSTRACT
941030
M94A0886

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .